Trending Industry Today: WUXI XDC Leads Gains In Biotech and Pharmaceutical Stocks
WuXi AppTec mid-year analysis: Biomedical industry recovery is already underway | Jian Zhi Research
Looking at the mid-year reports from CXO leaders such as WuXi AppTec, IQVIA, and Lonza, hand orders are exceeding expectations. Among them, WuXi AppTec's new hand order amount (excluding COVID-19 business) increased by 33.2%, far beyond the market expectations. The recovery trend of overseas biotech companies has already emerged.
B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $152.5
Zai Lab Analyst Ratings
Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research
The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.
WuXi AppTec Goes Ex Dividend Tomorrow